Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439–48.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531–44.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Dana H, Chalbatani GM, Jalali SA, Mirzaei HR, Grupp SA, Suarez ER, et al. CAR-T cells: early successes in blood cancer and challenges in solid tumors. Acta Pharm Sin B. 2021;11(5):1129–47.

CAS  PubMed  Article  Google Scholar 

Gerber DE, Pruitt SL, Halm EA. Should criteria for inclusion in cancer clinical trials be expanded? J Comp Eff Res. 2015;4(4):289–91.

PubMed  Article  Google Scholar 

Kevin Tang LJN. Real-world experiences of CAR T-cell therapy for large B-cell lymphoma: how similar are they to the prospective studies? J Immunother Precis Oncol. 2021;4(3):150–9.

PubMed  PubMed Central  Article  Google Scholar 

Kilgore KM, Mohammadi I, Schroeder A, Teigland C, Purdum A, Shah GL. Medicare patients receiving chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma: a first real-world look at patient characteristics, healthcare utilization, and costs. Blood. 2019;134(Supplement_1):793.

Article  Google Scholar 

Jacobson C, Hunter B, Armand P, Kamihara Y, Ritz J, Rodig S, et al. Axicabtagene ciloleucel in the real world: outcomes and predictors of response, resistance and toxicity. Blood. 2018;132(Supplement_1):92.

Article  Google Scholar 

Lyman GH, Nguyen A, Synder S. Economic evaluation of chimeric antigen receptor T-cell therapy by site of care among patients with relapsed or refractory large B-cell lymphoma. JAMA Netw Open. 2020;3(4): e202072.

PubMed  PubMed Central  Article  Google Scholar 

Myers GD, Verneris MR, Goy A, Maziarz RT. Perspectives on outpatient administration of CAR-T cell therapy in aggressive B-cell lymphoma and acute lymphoblastic leukemia. J Immunother Cancer. 2021;9(4): e002056.

PubMed  PubMed Central  Article  Google Scholar 

Dearment A. Outpatient use of CAR-Ts is enticing, but it comes with significant challenges too. 2020 June 3, 2020. https://medcitynews.com/2020/06/outpatient-use-of-car-ts-is-enticing-but-it-comes-with-significant-challenges-too/. Accessed 8 Mar 2022.

Bachier CR, Palomba ML, Abramson JS, Andreadis C, Sehgal AR, Godwin J, et al. Outpatient treatment with lisocabtagene maraleucel (liso-cel) in three ongoing clinical studies in relapsed/refractory (r/r) B cell non-Hodgkin lymphoma (NHL), including second-line transplant ineligible patients: transcend NHL 001, Outreach, and PILOT. Blood. 2019;134(Supplement_1):2868.

Article  Google Scholar 

Schuster SJ, Bishop MR, Tam C, Borchmann P, Jaeger U, Waller EK, et al. Sustained disease control for adult patients with relapsed or refractory diffuse large B-cell lymphoma: an updated analysis of Juliet, a global pivotal phase 2 trial of tisagenlecleucel. Blood. 2018;132(Supplement 1):1684.

Article  Google Scholar 

Jain T, Bar M, Kansagra AJ, Chong EA, Hashmi SK, Neelapu SS, et al. Use of chimeric antigen receptor T cell therapy in clinical practice for relapsed/refractory aggressive B cell non-hodgkin lymphoma: an expert panel opinion from the American society for transplantation and cellular therapy. Biol Blood Marrow Transplant. 2019;25(12):2305–21.

CAS  PubMed  Article  Google Scholar 

Kansagra AJ, Frey NV, Bar M, Laetsch TW, Carpenter PA, Savani BN, et al. Clinical utilization of chimeric antigen receptor T cells in B cell acute lymphoblastic leukemia: an expert opinion from the European society for blood and marrow transplantation and the American society for blood and marrow transplantation. Biol Blood Marrow Transplant. 2019;25(3):e76–85.

CAS  PubMed  Article  Google Scholar 

Caffrey M. Delays With Payers Mean Some Patients Miss Window for CAR T-Cell Therapy, Findings Show. 2021 April 26, 2021. https://www.ajmc.com/view/delays-with-payers-mean-some-patients-miss-window-for-car-t-cell-therapy-findings-show. Accessed 8 Mar 2022.

Nam S, Smith J, Yang G. Driving the Next Wave of Innovation in CAR T-cell Therapies. 2019 Dec. 13, 2019. https://www.mckinsey.com/industries/life-sciences/our-insights/driving-the-next-wave-of-innovation-in-car-t-cell-therapies. Accessed 8 Mar 2022.

Depil S, Duchateau P, Grupp SA, Mufti G, Poirot L. “Off-the-shelf” allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020;19(3):185–99.

CAS  PubMed  Article  Google Scholar 

Munshi NC, Anderson LD Jr, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705–16.

CAS  PubMed  Article  Google Scholar 

Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021;398(10297):314–24.

CAS  PubMed  Article  Google Scholar 

Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11(4):69.

PubMed  PubMed Central  Article  Google Scholar 

Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood. 2016;127(26):3321–30.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Brudno JN, Kochenderfer JN. Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management. Blood Rev. 2019;34:45–55.

CAS  PubMed  Article  Google Scholar 

Faramand R, Jain M, Staedtke V, Kotani H, Bai R, Reid K, et al. Tumor microenvironment composition and severe cytokine release syndrome (CRS) influence toxicity in patients with large B-cell lymphoma treated with axicabtagene ciloleucel. Clin Cancer Res. 2020;26(18):4823–31.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Murthy H, Iqbal M, Chavez JC, Kharfan-Dabaja MA. Cytokine release syndrome: current perspectives. Immunotargets Ther. 2019;8:43–52.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Namuduri M, Brentjens RJ. Medical management of side effects related to CAR T cell therapy in hematologic malignancies. Expert Rev Hematol. 2016;9(6):511–3.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol. 2020;17(3):147–67.

PubMed  Article  Google Scholar 

Giordano-Attianese G, Gainza P, Gray-Gaillard E, Cribioli E, Shui S, Kim S, et al. A computationally designed chimeric antigen receptor provides a small-molecule safety switch for T-cell therapy. Nat Biotechnol. 2020;38(4):426–32.

CAS  PubMed  Article  Google Scholar 

Chong EA, Ruella M, Schuster SJ. Five-year outcomes for refractory B-cell lymphomas with CAR T-cell therapy. N Engl J Med. 2021;384(7):673–4.

PubMed  Article  Google Scholar 

Jacobson C, Locke FL, Ghobadi A, Miklos DB, Lekakis LJ, Oluwole OO, et al. Long-term survival and gradual recovery of B cells in patients with refractory large B cell lymphoma treated with axicabtagene ciloleucel (Axi-Cel). Blood. 2020;136(Supplement_1):40–2.

Google Scholar 

Xu X, Qihang S, Liang X, Chen Z, Zhang X, Zhou X, et al. Mechanisms of relapse after CD19 CAR T-cell therapy for acute lymphoblastic leukemia and its prevention and treatment strategies. Front Immunol. 2019;10:2664.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Vercellino L, Di Blasi R, Kanoun S, Tessoulin B, Rossi C, D’Aveni-Piney M, et al. Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma. Blood Adv. 2020;4(22):5607–15.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Nie Y, Weiqing L, Chen D, Tu H, Guo Z, Zhou X, et al. Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies. Biomark Res. 2020;8:18.

PubMed  PubMed Central  Article  Google Scholar 

Jacobson C, Locke F, Ghobadi A, et al. Long-term (4- and 5-year) overall survival in ZUMA-1, the pivotal study of axicabtagene ciloleucel (Axi-Cel) in patients with refractory large B-cell lymphoma (LBCL). Blood. 2021;138(Supplement_1):1764.

Article  Google Scholar 

Nie Y, Weiqing L, Chen D, et al. Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies. Biomark Res. 2020;8:18.

PubMed  PubMed Central  Article  Google Scholar 

Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839–52.

PubMed  Article  Google Scholar 

Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382(14):1331–42.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021;398(10299):491–502.

CAS  PubMed  Article  Google Scholar 

Shah BD, Bishop MR, Oluwole OO, Logan AC, Baer MR, Donnellan WB, et al. KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. Blood. 2021;138(1):11–22.

CAS  PubMed  Article  Google Scholar 

Johnson PC, Jacobson C, Yi A, Saucier A, Dhawale TM, Nelson A, et al. Healthcare utilization and end-of-life outcomes in patients receiving CAR T-cell therapy. J Natl Compr Canc Netw. 2021;19:1–7.

Article  Google Scholar 

Purdum A, Johnson J, Bonagura A, Nyamutswa L, Elliot C, Lal LS. The first retrospective commercial claims-based analysis of CAR T treated patients with relapsed or refractory large B-cell lymphoma (R/R LBCL). Blood. 2020;136(Supplement_1):31.

Article